| 1 |
Gibb B, Hyman P, Schneider CL. The Many Applications of Engineered Bacteriophages-An Overview. Pharmaceuticals (Basel) 2021;14:634. [PMID: 34208847 DOI: 10.3390/ph14070634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Sáez Moreno D, Visram Z, Mutti M, Restrepo-Córdoba M, Hartmann S, Kremers AI, Tišáková L, Schertler S, Wittmann J, Kalali B, Monecke S, Ehricht R, Resch G, Corsini L. ε2-Phages Are Naturally Bred and Have a Vastly Improved Host Range in Staphylococcus aureus over Wild Type Phages. Pharmaceuticals (Basel) 2021;14:325. [PMID: 33918287 DOI: 10.3390/ph14040325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Au TY, Assavarittirong C. Combating antimicrobial resistance: an evidence-based overview of bacteriophage therapy. Postgrad Med J 2022:postgradmedj-2022-141546. [PMID: 35379752 DOI: 10.1136/postgradmedj-2022-141546] [Reference Citation Analysis]
|
| 4 |
Cruz KCP, Enekegho LO, Stuart DT. Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases. Front Bioeng Biotechnol 2022;10:890479. [DOI: 10.3389/fbioe.2022.890479] [Reference Citation Analysis]
|
| 5 |
Marongiu L, Burkard M, Venturelli S, Allgayer H. Dietary Modulation of Bacteriophages as an Additional Player in Inflammation and Cancer. Cancers (Basel) 2021;13:2036. [PMID: 33922485 DOI: 10.3390/cancers13092036] [Reference Citation Analysis]
|
| 6 |
Dowdell AS, Colgan SP. Metabolic Host-Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD). Pharmaceuticals (Basel) 2021;14:708. [PMID: 34451805 DOI: 10.3390/ph14080708] [Reference Citation Analysis]
|
| 7 |
Wang Y, Sheng J, Chai J, Zhu C, Li X, Yang W, Cui R, Ge T. Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy. Front Immunol 2021;12:729336. [PMID: 34566987 DOI: 10.3389/fimmu.2021.729336] [Reference Citation Analysis]
|
| 8 |
Hashemi Shahraki A, Mirsaeidi M. Phage Therapy for Mycobacterium Abscessus and Strategies to Improve Outcomes. Microorganisms 2021;9:596. [PMID: 33799414 DOI: 10.3390/microorganisms9030596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med 2022;28:690-703. [PMID: 35440726 DOI: 10.1038/s41591-022-01779-2] [Reference Citation Analysis]
|
| 10 |
Zhang Y, Saint Fleur A, Feng H. The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota. Gut Microbes 2022;14:2052698. [PMID: 35319337 DOI: 10.1080/19490976.2022.2052698] [Reference Citation Analysis]
|
| 11 |
Bhat P, Garibyan L. The potential of CRISPR guided therapies in the dermatology clinic. JID Innovations 2022. [DOI: 10.1016/j.xjidi.2022.100103] [Reference Citation Analysis]
|
| 12 |
Kreis V, Soutourina O. Clostridioides difficile - phage relationship the RNA way. Curr Opin Microbiol 2021;66:1-10. [PMID: 34922145 DOI: 10.1016/j.mib.2021.11.012] [Reference Citation Analysis]
|
| 13 |
Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, Ruan Z. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnology 2021;19:401. [PMID: 34863214 DOI: 10.1186/s12951-021-01132-8] [Reference Citation Analysis]
|
| 14 |
Łobocka M, Dąbrowska K, Górski A. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. BioDrugs 2021;35:255-80. [PMID: 33881767 DOI: 10.1007/s40259-021-00480-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 15 |
Nale JY, Clokie MR. Preclinical data and safety assessment of phage therapy in humans. Curr Opin Biotechnol 2021;68:310-7. [PMID: 33862490 DOI: 10.1016/j.copbio.2021.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 16 |
Palacios Araya D, Palmer KL, Duerkop BA. CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria. PLoS Pathog 2021;17:e1009672. [PMID: 34237097 DOI: 10.1371/journal.ppat.1009672] [Reference Citation Analysis]
|
| 17 |
Phothichaisri W, Chankhamhaengdecha S, Janvilisri T, Nuadthaisong J, Phetruen T, Fagan RP, Chanarat S. Potential Role of the Host-Derived Cell-Wall Binding Domain of Endolysin CD16/50L as a Molecular Anchor in Preservation of Uninfected Clostridioides difficile for New Rounds of Phage Infection. Microbiol Spectr 2022;:e0236121. [PMID: 35377223 DOI: 10.1128/spectrum.02361-21] [Reference Citation Analysis]
|
| 18 |
Peng H, Rossetto D, Mansy SS, Jordan MC, Roos KP, Chen IA. Treatment of Wound Infections in a Mouse Model Using Zn2+-Releasing Phage Bound to Gold Nanorods. ACS Nano 2022. [PMID: 35239330 DOI: 10.1021/acsnano.2c00048] [Reference Citation Analysis]
|
| 19 |
Lam KN, Spanogiannopoulos P, Soto-Perez P, Alexander M, Nalley MJ, Bisanz JE, Nayak RR, Weakley AM, Yu FB, Turnbaugh PJ. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep 2021;37:109930. [PMID: 34731631 DOI: 10.1016/j.celrep.2021.109930] [Reference Citation Analysis]
|
| 20 |
Parsons C, Brown P, Kathariou S. Use of Bacteriophage Amended with CRISPR-Cas Systems to Combat Antimicrobial Resistance in the Bacterial Foodborne Pathogen Listeria monocytogenes. Antibiotics (Basel) 2021;10:308. [PMID: 33802904 DOI: 10.3390/antibiotics10030308] [Reference Citation Analysis]
|
| 21 |
Javaudin F, Latour C, Debarbieux L, Lamy-Besnier Q. Intestinal Bacteriophage Therapy: Looking for Optimal Efficacy. Clin Microbiol Rev 2021;:e0013621. [PMID: 34668734 DOI: 10.1128/CMR.00136-21] [Reference Citation Analysis]
|
| 22 |
Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
|
| 23 |
Zhan Y, Li XP, Yin JY. COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19. Int J Biol Sci 2021;17:2080-8. [PMID: 34131407 DOI: 10.7150/ijbs.60655] [Reference Citation Analysis]
|
| 24 |
Coleman ME, Dietert RR, North DW, Stephenson MM. Enhancing Human Superorganism Ecosystem Resilience by Holistically ‘Managing Our Microbes’. Applied Microbiology 2021;1:471-97. [DOI: 10.3390/applmicrobiol1030031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Meile S, Du J, Dunne M, Kilcher S, Loessner MJ. Engineering therapeutic phages for enhanced antibacterial efficacy. Curr Opin Virol 2021;52:182-91. [PMID: 34952266 DOI: 10.1016/j.coviro.2021.12.003] [Reference Citation Analysis]
|
| 26 |
Yeh TK, Jean SS, Lee YL, Lu MC, Ko WC, Lin HJ, Liu PY, Hsueh PR. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. Int J Antimicrob Agents 2021;:106475. [PMID: 34767917 DOI: 10.1016/j.ijantimicag.2021.106475] [Reference Citation Analysis]
|
| 27 |
Duan C, Cao H, Zhang LH, Xu Z. Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance. Front Microbiol 2021;12:716064. [PMID: 34489905 DOI: 10.3389/fmicb.2021.716064] [Reference Citation Analysis]
|
| 28 |
Loose M, Sáez Moreno D, Mutti M, Hitzenhammer E, Visram Z, Dippel D, Schertler S, Tišáková LP, Wittmann J, Corsini L, Wagenlehner F. Natural Bred ε2-Phages Have an Improved Host Range and Virulence against Uropathogenic Escherichia coli over Their Ancestor Phages. Antibiotics (Basel) 2021;10:1337. [PMID: 34827275 DOI: 10.3390/antibiotics10111337] [Reference Citation Analysis]
|
| 29 |
Peng W, Zeng F, Wu Z, Jin Z, Li W, Zhu M, Wang Q, Tong Y, Chen L, Bai Q. Isolation and genomic analysis of temperate phage 5W targeting multidrug-resistant Acinetobacter baumannii. Arch Microbiol 2022;204. [DOI: 10.1007/s00203-021-02618-7] [Reference Citation Analysis]
|
| 30 |
Azam AH, Tan XE, Veeranarayanan S, Kiga K, Cui L. Bacteriophage Technology and Modern Medicine. Antibiotics (Basel) 2021;10:999. [PMID: 34439049 DOI: 10.3390/antibiotics10080999] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 31 |
León Y, Faherty CS. Bacteriophages against enteropathogens: rediscovery and refinement of novel antimicrobial therapeutics. Curr Opin Infect Dis 2021;34:491-9. [PMID: 34524200 DOI: 10.1097/QCO.0000000000000772] [Reference Citation Analysis]
|
